Argenica Therapeutics Ltd

Chart & performance

D1W1MN

P/E

—

P/S

—

EPS

—

Div yield, %

—

Shrs. gr., 5y

11.91%

Rev. gr., 5y

Revenues

-100.00%

Net income

-1m

L-80.96%

CFO

-4m

L-26.55%

Notes

No notes on this company yet

Write a private note on this company, for your eyes only

Add note

Profile

Argenica Therapeutics Limited, a biotechnology company, engages in the research and development of neuroprotective therapeutic drugs in Australia. Its lead product candidate is ARG-007, a neuroprotective peptide candidate, which is in phase 2 clinical trial to reduce brain tissue death after stroke and other types of brain injury. The company was incorporated in 2019 and is based in Nedlands, Australia.

Key people

Liz Dallimore

Chief Executive Officer, Managing Director, Executive Director · since 2022

Emma Waldon

Company Secretary · since 2019

Mark Etherton

Non-Executive Director · since 2024

Jeannie Joughin

Non-Executive Independent Director · since 2024

URL

https://argenica.com.au/

IPO date

Jun 11, 2021

Employees

Domiciled in

Incorporated in

Valuation

Order:

Title AUD in thousands, except ratios and share amounts	FY	FY	FY	FY	FY	FY	FY
Title AUD in thousands, except ratios and share amounts	2026‑06	2025‑06	2024‑06	2023‑06	2022‑06	2021‑06	2020‑06
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT